Clinical trials: HPV Cancers
Human Papilloma Virus, Human Papilloma Virus Infection
Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV-HR.
- Conditions
- Human Papilloma Virus, Human Papilloma Virus Infection, Cervix Lesion
- Trial name
- PALOMA2 (NCT04199078)
- Testing
- Papilocare vaginal gel
- Where
- 19 sites in Spain
- Volunteers
- 164 people
- Sponsor
- Procare Health Iberia S.L.
Infections, Papillomavirus
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This study will further evaluate induction of immune memory and anamnestic responses in women who previously took…
- Trial name
- NCT00546078
- Testing
- Cervarix™
- Where
- 17 sites in United States, Canada
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Condylomata Acuminata
Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts
The purpose of this study is to investigate the clinical efficacy, safety and tolerability of a Polyphenon E Ointment 10% and a Polyphenon E Ointment 15% in the treatment of external genitial warts in male and female patients.
- Trial name
- NCT00449982
- Testing
- Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 480 people
- Sponsor
- MediGene
HPV Infections
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
To prove that quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine is generally safe and well tolerated in the Chinese population.
- Trial name
- NCT00635830
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Warts
Study With a Topical Gel to Treat Common Warts in Adults
The primary purpose of this study is to evaluate the effectiveness in adults of 2 different strengths of resiquimod gel applied to common wart(s) five times a week for up to 12 weeks.
- Trial name
- NCT00117871
- Testing
- Resiquimod
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Papillomavirus Infections
A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects
The purpose of this study is to evaluate the safety, tolerability, and the immunological effects of adeno-associated virus-like particle human papillomavirus (AAVLP-HPV) vaccine in healthy adults.
- Trial name
- NCT03929172
- Testing
- AAVLP-HPV
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- 2A Pharma AB
Papillomavirus Infections
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa.
- Trial name
- NCT01245764
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Vulvar Intraepithelial Neoplasia Grade 2, Vulvar Intraepithelial Neoplasia Grade 3
Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)
This is a multicentre open labelled phase I trial evaluating the safety and preliminary efficacy of local decitabine treatment of human papillomavirus (HPV)-induced vulvar intraepithelial neoplasia (VIN) grade 2/3.
- Trial name
- DelVIN (NCT05717621)
- Testing
- VTD-101 ointment
- Where
- 5 sites in Germany
- Volunteers
- 29 people
- Sponsor
- ViMREX GmbH
Papillomatosis, HIV Infections
Treatment of Oral Warts in HIV+ Patients
This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults.
- Trial name
- NCT00454181
- Testing
- Interferon-alpha
- Where
- 12 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00196937
- Testing
- Cervarix
- Where
- 6 sites in Germany, Poland
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Warts
Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
This is a placebo-controlled, double-blind (subject, Investigator, and site staff with the exception of unblinded dedicated staff to handle study medication), phase 2a study with 3 dose cohorts, randomized (concealed) to CANDIN…
- Trial name
- NCT02393417
- Testing
- CANDIN
- Where
- 15 sites in United States
- Volunteers
- 243 people
- Sponsor
- Nielsen BioSciences, Inc.
Infections, Papillomavirus
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in…
- Trial name
- NCT01190189
- Testing
- GSK580299 (Cervarix)
- Where
- 28 sites in United States, Canada
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neoplasms, Rectal
A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea
The purpose of this post-marketing surveillance (PMS) study is to collect safety information on the use of Cervarix upon the expanded indication to anal cancer to both women and men (at least 600 Korean women and men) within 30…
- Trial name
- NCT03671369
- Testing
- Safety data collection (following routine vaccination) by a continuous surveillance method.
- Where
- 29 sites in South Korea
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
High-risk HPV Infection and Biopsy-proven CIN1
An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101
Phase I, open-label, sequential-cohort, ascending multiple-dose study to evaluate the safety and tolerability of escalating doses of PDS0101 in female subjects with high-risk HPV infection and biopsy-proven CIN1.
- Trial name
- NCT02065973
- Testing
- R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- PDS Biotechnology Corp.
Meningococcal Meningitis, Human Papillomavirus Infection
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents
- Conditions
- Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis, Tetanus
- Trial name
- NCT00518180
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine, Tdap Vaccine
- Where
- Costa Rica
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Cervical Cancer, Genital Wart
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.
- Conditions
- Cervical Cancer, Genital Wart, CIN, VIN
- Trial name
- NCT05580341
- Testing
- Zerun HPV-9, GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Condylomata Acuminata, Papillomavirus Infections
Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
Ranpirnase in topical formulation is an antiviral drug being evaluated for the topical treatment of anogenital warts. The aims of this study is to evaluate the efficacy and safety of a topical formulation of ranpirnase in…
- Conditions
- Condylomata Acuminata, Papillomavirus Infections, Sexually Transmitted Diseases
- Trial name
- NCT02535104
- Testing
- Ranpirnase, Vehicle
- Where
- Bolivia
- Volunteers
- 70 people
- Sponsor
- Tamir Biotechnology, Inc.
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
The purpose of this study was to evaluate the safety, efficacy, and immunogenicity of V503 in comparison to GARDASIL. The primary hypotheses tested in the study were 1) V503 administered to 16- to 26-year-old adolescents and…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00543543
- Testing
- Comparator: GARDASIL, Experimental: V503
- Volunteers
- 14,840 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections
A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)
Researchers want to learn if V503 (also called the 9-valent human papillomavirus [9vHPV] vaccine, recombinant) can induce an immune response to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Chinese females who previously…
- Trial name
- NCT07785843
- Testing
- V503
- Where
- China
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00316693
- Testing
- HPV-16/18 vaccine (Cervarix™), Aimmugen™
- Where
- 4 sites in Japan
- Volunteers
- 1,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline